Nanobiotix S.A. (NBTX) Financial Ratios
14 years of historical data (2011–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
N/A
—
5yr avg: 8.11
30Y Low5.7·High10.5
ROE
↑
N/A
—
5yr avg: -97.4%
30Y Low-133%·High-57%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
NBTX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Nanobiotix S.A. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2.1B | $136M | $269M | $128M | $281M | $402M | — | — | — | — | — |
| Enterprise Value | $2.1B | $137M | $244M | $140M | $243M | $332M | — | — | — | — | — |
| P/E Ratio → | -25.22 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | 7.42 | 26.78 | 106.29 | 8047.32 | — | — | — | — | — |
| P/B Ratio | — | — | — | — | 10.50 | 5.71 | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
NBTX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | 6.74 | 29.25 | 91.97 | 6643.88 | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
NBTX Profitability
Margins and return-on-capital ratios measuring operating efficiency
Nanobiotix S.A. earns an operating margin of 589.1%. Operating margins have expanded from -977.8% to 589.1% over the past 3 years, signaling improving operational efficiency.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 100.0% | 79.4% | 100.0% | 100.0% | 100.0% | 100.0% | -37.2% | 72.0% | -35.4% |
| Operating Margin | 589.1% | 589.1% | -74.0% | -977.8% | -1986.4% | -72856.0% | -68792.6% | -25919.8% | -10027.9% | -1402.6% | -6455.3% |
| Net Profit Margin | 586.9% | 586.9% | -109.6% | -1194.4% | -1775.7% | -67246.0% | -74875.0% | -25772.4% | -10375.6% | -1404.3% | -6403.1% |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | -96.7% | -98.1% | -825.6% | -102.8% | -85.3% | -132.6% | -74.0% |
| ROA | -84.5% | -84.5% | -51.7% | -70.6% | -39.9% | -35.3% | -99.4% | -57.7% | -59.5% | -77.0% | -53.6% |
| ROIC | — | — | — | — | — | -698.8% | -1153.3% | — | -1099.7% | -628.4% | -898.7% |
| ROCE | -260.5% | -260.5% | -81.3% | -107.7% | -58.4% | -46.5% | -122.4% | -72.7% | -71.9% | -105.4% | -66.0% |
NBTX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $1M ($51M total debt minus $50M cash).
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | 1.72 | 0.70 | — | 1.44 | 0.11 | 0.33 | 0.29 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | — | — | -1.41 | -1.00 | — | -1.10 | -0.97 | -0.88 | -0.79 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -8.46 | -8.46 | -3.35 | -8.00 | -78.36 | -109.39 | -9.76 | -35.50 | -233.16 | -213.84 | -288.01 |
NBTX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.04x means Nanobiotix S.A. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has declined from 1.38x to 1.04x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.04 | 1.04 | 1.75 | 1.38 | 2.53 | 6.58 | 3.22 | 3.68 | 5.68 | 3.26 | 3.23 |
| Quick Ratio | 1.04 | 1.04 | 1.75 | 1.30 | 2.61 | 6.58 | 3.03 | 3.58 | 6.20 | 3.87 | 3.06 |
| Cash Ratio | 0.84 | 0.84 | 1.51 | 1.09 | 2.28 | 6.26 | 2.45 | 3.12 | 5.05 | 2.55 | 2.39 |
| Asset Turnover | — | -0.17 | 0.39 | 0.08 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 | 0.01 |
| Inventory Turnover | 0.33 | — | — | 0.33 | — | — | — | — | — | — | 0.30 |
| Days Sales Outstanding | — | -268.35 | 29.91 | 217.20 | 955.04 | 28324.00 | 6741.76 | 3137.11 | 1222.62 | 1.22 | 972.32 |
NBTX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Nanobiotix S.A. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — | — |
| Shares Outstanding | — | $47M | $37M | $35M | $35M | $24M | $22M | $20M | $17M | $15M | $14M |
Peer Comparison
Compare NBTX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 NBTXYou | $2B | -25.2 | — | — | 100.0% | 589.1% | — | — | — |
 NVCR | $2B | -13.8 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — |
 ARAY | $35M | -18.9 | 11.0 | — | 32.1% | 1.7% | -2.5% | 3.0% | 12.6 |
 SENS | $224M | -3.2 | — | — | 44.7% | -193.8% | -310.7% | -322.6% | — |
 ONCO | $1M | -0.1 | — | — | 77.6% | -778.2% | -110.6% | -32.8% | — |
 CELC | $6B | -46.2 | — | — | — | — | -87.5% | -50.3% | — |
 AGEN | $132M | -1102.9 | — | — | 90.3% | -18.0% | — | — | — |
 IMVT | $6B | -10.0 | — | — | — | — | -62.5% | — | — |
 CLDX | $2B | -8.5 | — | — | 100.0% | -19160.0% | -40.6% | -35.2% | — |
 NKTR | $2B | -8.6 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 HALO | $8B | 25.5 | 8.3 | 11.9 | 78.1% | 58.4% | 153.6% | 73.4% | — |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 14 years · Updated daily
See NBTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs NBTX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare NBTX vs NVCR
Side-by-side business, growth, and profitability comparison vs NovoCure Limited.
Start ComparisonNBTX — Frequently Asked Questions
Quick answers to the most common questions about buying NBTX stock.
What is Nanobiotix S.A.'s P/E ratio?
Nanobiotix S.A.'s current P/E ratio is -25.2x. This places it at the 50th percentile of its historical range.
Is NBTX stock overvalued?
Based on historical data, Nanobiotix S.A. is trading at a P/E of -25.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Nanobiotix S.A.'s profit margins?
Nanobiotix S.A. has 100.0% gross margin and 589.1% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.